Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 517.97
NAS:TGTX's Cash to Debt is ranked higher than
56% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:TGTX: 517.97 )
Ranked among companies with meaningful Cash to Debt only.
NAS:TGTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: 517.97
Equity to Asset 0.75
NAS:TGTX's Equity to Asset is ranked higher than
59% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:TGTX: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
NAS:TGTX' s Equity to Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.87 Max: 0.97
Current: 0.75
0.16
0.97
F-Score: 3
Z-Score: 3.36
M-Score: -4.58
WACC vs ROIC
18.88%
-368.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -47750.00
NAS:TGTX's Operating margin (%) is ranked lower than
98% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:TGTX: -47750.00 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:TGTX' s Operating margin (%) Range Over the Past 10 Years
Min: -141552.63  Med: -39112.17 Max: -15109.21
Current: -47750
-141552.63
-15109.21
Net-margin (%) -47494.08
NAS:TGTX's Net-margin (%) is ranked lower than
98% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:TGTX: -47494.08 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:TGTX' s Net-margin (%) Range Over the Past 10 Years
Min: -95121.05  Med: -39055.93 Max: -13472.37
Current: -47494.08
-95121.05
-13472.37
ROE (%) -81.52
NAS:TGTX's ROE (%) is ranked lower than
74% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:TGTX: -81.52 )
Ranked among companies with meaningful ROE (%) only.
NAS:TGTX' s ROE (%) Range Over the Past 10 Years
Min: -3919.22  Med: -92.85 Max: -40.04
Current: -81.52
-3919.22
-40.04
ROA (%) -70.58
NAS:TGTX's ROA (%) is ranked lower than
79% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:TGTX: -70.58 )
Ranked among companies with meaningful ROA (%) only.
NAS:TGTX' s ROA (%) Range Over the Past 10 Years
Min: -543.33  Med: -88.95 Max: 6.57
Current: -70.58
-543.33
6.57
ROC (Joel Greenblatt) (%) -5429.91
NAS:TGTX's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:TGTX: -5429.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:TGTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -58800  Med: -13407.82 Max: -5429.91
Current: -5429.91
-58800
-5429.91
Revenue Growth (3Y)(%) 44.20
NAS:TGTX's Revenue Growth (3Y)(%) is ranked higher than
88% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:TGTX: 44.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:TGTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: 44.2
0
44.2
EBITDA Growth (3Y)(%) -10.60
NAS:TGTX's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:TGTX: -10.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:TGTX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -70 Max: 73
Current: -10.6
0
73
» NAS:TGTX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

TGTX Guru Trades in Q1 2015

Jim Simons 19,399 sh (-87.71%)
» More
Q2 2015

TGTX Guru Trades in Q2 2015

Jim Simons Sold Out
» More
Q2 2016

TGTX Guru Trades in Q2 2016

Paul Tudor Jones 23,516 sh (New)
» More
Q3 2016

TGTX Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TGTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CGEN, NAS:TRVN, NAS:CRVS, OTCPK:TYMI, NAS:SYRS, OTCPK:SPHDF, NAS:PRTK, NAS:FOMX, NAS:PTI, NAS:MESO, NAS:CEMP, NAS:CRBP, NAS:SRNE, NAS:AKBA, NAS:OCUL, NAS:SPPI, NAS:PETX, NAS:ARWR, NAS:SVA, NAS:ADAP » details
Traded in other countries:NKB2.Germany,
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.

TG Therapeutics Inc, was incorporated in Delaware in 1993. The Company is a biopharmaceutical company focused on the acquisition, development, and commercialization of new and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the Company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 or ublituximab which is a novel, third generation monoclonal antibody that targets a specific and single epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases or PI3Ks are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K: alpha, beta, delta, and gamma, of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers. The Company competes with Roche Group, Gazyva, Spectrum Pharmaceutical, Dr. Reddy's Laboratories', among others.

Ratios

vs
industry
vs
history
P/B 5.05
TGTX's P/B is ranked lower than
66% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. TGTX: 5.05 )
Ranked among companies with meaningful P/B only.
TGTX' s P/B Range Over the Past 10 Years
Min: 2.51  Med: 6.12 Max: 17.69
Current: 5.05
2.51
17.69
P/S 1311.94
TGTX's P/S is ranked lower than
98% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. TGTX: 1311.94 )
Ranked among companies with meaningful P/S only.
TGTX' s P/S Range Over the Past 10 Years
Min: 558.33  Med: 2110 Max: 4670
Current: 1311.94
558.33
4670
Current Ratio 4.23
TGTX's Current Ratio is ranked higher than
50% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. TGTX: 4.23 )
Ranked among companies with meaningful Current Ratio only.
TGTX' s Current Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.39 Max: 35.5
Current: 4.23
0.06
35.5
Quick Ratio 4.23
TGTX's Quick Ratio is ranked higher than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. TGTX: 4.23 )
Ranked among companies with meaningful Quick Ratio only.
TGTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 4.39 Max: 35.5
Current: 4.23
0.06
35.5
Days Sales Outstanding 259.34
TGTX's Days Sales Outstanding is ranked lower than
94% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. TGTX: 259.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
TGTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.84  Med: 206.51 Max: 446.64
Current: 259.34
64.84
446.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.90
TGTX's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. TGTX: -27.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TGTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -851.2  Med: -14.5 Max: 0
Current: -27.9
-851.2
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.84
TGTX's Price/Net Cash is ranked lower than
58% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. TGTX: 6.84 )
Ranked among companies with meaningful Price/Net Cash only.
TGTX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.68  Med: 7.79 Max: 620.4
Current: 6.84
1.68
620.4
Price/Net Current Asset Value 5.42
TGTX's Price/Net Current Asset Value is ranked lower than
52% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. TGTX: 5.42 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TGTX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.63  Med: 7.25 Max: 3515.58
Current: 5.42
1.63
3515.58
Price/Tangible Book 5.10
TGTX's Price/Tangible Book is ranked lower than
58% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. TGTX: 5.10 )
Ranked among companies with meaningful Price/Tangible Book only.
TGTX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.62  Med: 6.83 Max: 5631.96
Current: 5.1
1.62
5631.96
Price/Median PS Value 0.62
TGTX's Price/Median PS Value is ranked higher than
71% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. TGTX: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
TGTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 0.79 Max: 1.96
Current: 0.62
0.01
1.96
Earnings Yield (Greenblatt) (%) -31.46
TGTX's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. TGTX: -31.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TGTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -32.63  Med: 194.4 Max: 1470.1
Current: -31.46
-32.63
1470.1

More Statistics

Revenue (TTM) (Mil) $0.15
EPS (TTM) $ -1.48
Beta2.16
Short Percentage of Float23.02%
52-Week Range $4.90 - 13.55
Shares Outstanding (Mil)54.73

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 0 0 6 23
EPS ($) -1.40 -1.34 -1.44 -1.52
EPS w/o NRI ($) -1.40 -1.34 -1.44 -1.52
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:TGTX

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 

More From Other Websites
ETFs with exposure to TG Therapeutics, Inc. : December 9, 2016 Dec 09 2016
TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 8, 2016 Dec 08 2016
TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 06 2016
TG Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations at the 58th... Dec 06 2016
TG Therapeutics, Inc. Announces that the GENUINE Phase 3 Study has Reached Target Enrollment Dec 06 2016
TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 05 2016
TG Therapeutics, Inc. Announces Oral Data Presentation for TGR-1202 in Combination with Ibrutinib in... Dec 05 2016
TG Therapeutics, Inc. Announces Preclinical Data Presentations for TGR-1202 at the 58th American... Dec 05 2016
TG Therapeutics, Inc. Recaps Schedule of Data Presentations at the 58th American Society of... Dec 02 2016
Edited Transcript of TGTX earnings conference call or presentation 7-Nov-16 1:30pm GMT Nov 23 2016
TG Therapeutics Announces Positive DSMB Recommendation for Continuation of the UNITY-CLL Phase 3... Nov 22 2016
TG Therapeutics Announces Positive DSMB Recommendation for Continuation of the UNITY-CLL Phase 3... Nov 22 2016
TG THERAPEUTICS, INC. Financials Nov 17 2016
TG THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
TG Therapeutics reports 3Q loss Nov 07 2016
TG Therapeutics reports 3Q loss Nov 07 2016
TG THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 07 2016
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2016 Financial Results Nov 07 2016
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2016 Financial Results Nov 07 2016
Q3 2016 TG Therapeutics Inc Earnings Release - After Market Close Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)